JP5269795B2 - カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体 - Google Patents

カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体 Download PDF

Info

Publication number
JP5269795B2
JP5269795B2 JP2009530273A JP2009530273A JP5269795B2 JP 5269795 B2 JP5269795 B2 JP 5269795B2 JP 2009530273 A JP2009530273 A JP 2009530273A JP 2009530273 A JP2009530273 A JP 2009530273A JP 5269795 B2 JP5269795 B2 JP 5269795B2
Authority
JP
Japan
Prior art keywords
chlorophenyl
dichlorophenyl
pyrazol
methyl
oxadiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009530273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504961A (ja
Inventor
リ・ジンフワ
キム・ジョンミン
チョンフワン・ジョナサン・チャン
リ・スクホ
ソ・へジョン
カン・スクヨン
ソン・クワンソプ
キム・ジョンユプ
キム・ミンジュ
リ・スンハン
アーン・クワンウ
ジュン・ミュンウン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Green Cross Corp
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/541,269 external-priority patent/US20080081815A1/en
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of JP2010504961A publication Critical patent/JP2010504961A/ja
Application granted granted Critical
Publication of JP5269795B2 publication Critical patent/JP5269795B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2009530273A 2006-09-29 2007-09-28 カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体 Expired - Fee Related JP5269795B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/541,269 2006-09-29
US11/541,269 US20080081815A1 (en) 2006-09-29 2006-09-29 Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
KR10-2006-0132606 2006-12-22
KR20060132606 2006-12-22
PCT/KR2007/004754 WO2008039023A1 (fr) 2006-09-29 2007-09-28 Dérivés d'hétéroaryl-pyrazole utilisés en tant qu'antagonistes du récepteur cb1 des cannabinoïdes

Publications (2)

Publication Number Publication Date
JP2010504961A JP2010504961A (ja) 2010-02-18
JP5269795B2 true JP5269795B2 (ja) 2013-08-21

Family

ID=39234790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530273A Expired - Fee Related JP5269795B2 (ja) 2006-09-29 2007-09-28 カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体

Country Status (5)

Country Link
EP (1) EP2097410A4 (fr)
JP (1) JP5269795B2 (fr)
KR (1) KR101100028B1 (fr)
CN (1) CN101528740B (fr)
WO (1) WO2008039023A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
ES2390560T3 (es) * 2008-04-22 2012-11-14 Eli Lilly And Company Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos CB-1
AU2009238444B2 (en) * 2008-04-22 2013-08-29 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
ES2639940T3 (es) 2011-04-27 2017-10-30 Shionogi & Co., Ltd. Derivado heterocíclico aromático de 5 miembros anillo que tiene actividad antagonista del receptor Y5 de NPY
WO2013005168A2 (fr) * 2011-07-05 2013-01-10 Lupin Limited Modulateurs des récepteurs de cannabinoïdes
TWI673429B (zh) 2013-03-14 2019-10-01 美商漢特道格拉斯股份有限公司 用以控制建築開口遮蓋物總成之方法及裝置
WO2015162452A1 (fr) * 2014-04-23 2015-10-29 Piramal Enterprises Limited Composés pyrazole substitués comme antagonistes du récepteur cb1 et leurs utilisations
CN108586436A (zh) * 2018-07-06 2018-09-28 南京大学 一类含吲哚骨架的双酰肼类衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
EP1300159B1 (fr) * 2000-06-29 2007-10-10 Anthera Pharmaceuticals, Inc. Remedes contre le cancer
CN1638776A (zh) * 2001-06-08 2005-07-13 西托维亚公司 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
JP2006514693A (ja) 2002-12-18 2006-05-11 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害剤
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
JP2007530690A (ja) * 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP2097410A1 (fr) 2009-09-09
WO2008039023A1 (fr) 2008-04-03
CN101528740A (zh) 2009-09-09
JP2010504961A (ja) 2010-02-18
CN101528740B (zh) 2012-09-19
KR20090061076A (ko) 2009-06-15
EP2097410A4 (fr) 2009-11-25
KR101100028B1 (ko) 2011-12-29

Similar Documents

Publication Publication Date Title
JP5269795B2 (ja) カンナビノイドｃｂ１受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体
CA2885180C (fr) Antagonistes des recepteurs de l'orexine, qui sont des derives [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
CA2988147C (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
JP5878859B2 (ja) ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体
AU2006331437B2 (en) Aryl-Isoxazol-4-yl-Imidazole derivatives
CA2484188C (fr) Antagonistes du recepteur tachykinine
IL285246B1 (en) Substitute bicyclic compounds as modular FARNESOID X receptors
WO2012020820A1 (fr) Dérivé d'hétéroaryl pyrazole
TW200920356A (en) Aminoalkylazole derivatives as histamine-3 antagonists
CA2902135A1 (fr) Derives d'amide d'azetidine en tant qu'antagonistes des recepteurs d'orexine
US7875647B2 (en) Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
CA3109623C (fr) Composes de benzimidazole et leur utilisation pour traiter la maladie d'alzheimer ou la maladie de huntington
US20080207704A1 (en) Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
WO2009078498A1 (fr) Biarylpyrazole-4-carboxamides comme ligands des récepteurs cannabinoïdes cb1
US20080081815A1 (en) Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
US8309584B2 (en) Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists
US20080207705A1 (en) Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists
EA035585B1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130508

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees